Skip to main content

Advertisement

Fig. 3 | Journal of Translational Medicine

Fig. 3

From: Gemcitabine reduces MDSCs, tregs and TGFβ-1 while restoring the teff/treg ratio in patients with pancreatic cancer

Fig. 3

The effect of gemcitabine on immunomodulatory plasma proteins. Ten pancreatic cancer patients were sampled during the first cycle of gemcitabine treatment, where gemcitabine was given once weekly for 3 weeks, followed by a resting period. Blood samples were collected at day 1, 8, 15 and 29 always before gemcitabine was given that day. Plasma levels of Arginase-1, MPO and TGFβ-1 were evaluated by ELISA (ac) and MDS multiplex analysis was performed for determining plasma levels of IL-1β, IL-6, IL-8, IL-10 and TNFα (dh). Concentrations are displayed in ng/mL or pg/mL and statistical differences were assessed by Wilcoxon matched-pairs signed-rank test (*P < 0.05, ** P < 0.01)

Back to article page